Correction: Circulating levels of PCSK9, ANGPTL3 and lp(a) in stage III breast cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Correction: Circulating levels of PCSK9, ANGPTL3 and lp(a) in stage III breast cancers ; volume:24 ; number:1 ; day:15 ; month:11 ; year:2024 ; pages:1-2 ; date:12.2024
BMC cancer ; 24, Heft 1 (15.11.2024), 1-2, 12.2024
- Creator
-
Chong, Emilie Wong
Joncas, France-Hélène
Seidah, Nabil G.
Calon, Frédéric
Diorio, Caroline
Ganglof, Anne
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-13182-w
- URN
-
urn:nbn:de:101:1-2502040844259.411762281065
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chong, Emilie Wong
- Joncas, France-Hélène
- Seidah, Nabil G.
- Calon, Frédéric
- Diorio, Caroline
- Ganglof, Anne
- SpringerLink (Online service)
Other Objects (12)
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
LPA, Abt. LP 4 (Flak).- Personalangelegenheiten
Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification
Lp(a): a New Pathway to Target?
Lp(a) in der Routinelipiddiagnostik : Methoden und Interferenzen
Untersuchungen zum Lp(a) bei Typ-II-Diabetes
Lp(a) als unabhängiger Risikofaktor für eine KHK
Editorial Lp(a) – the underestimated cardiovascular risk factor
Lp(a) als Risikofaktor einer koronaren Herzkrankheit : eine Grenzwertbestimmung
Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region
An LC–MS-based designated comparison method with similar performance to the Lp(a) reference measurement procedure to guide molar Lp(a) standardization
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
LPA, Abt. LP 4 (Flak).- Personalangelegenheiten
Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification
Lp(a): a New Pathway to Target?
Lp(a) in der Routinelipiddiagnostik : Methoden und Interferenzen
Untersuchungen zum Lp(a) bei Typ-II-Diabetes
Lp(a) als unabhängiger Risikofaktor für eine KHK
Editorial Lp(a) – the underestimated cardiovascular risk factor
Lp(a) als Risikofaktor einer koronaren Herzkrankheit : eine Grenzwertbestimmung
Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region
An LC–MS-based designated comparison method with similar performance to the Lp(a) reference measurement procedure to guide molar Lp(a) standardization
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
LPA, Abt. LP 4 (Flak).- Personalangelegenheiten
Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification
Lp(a): a New Pathway to Target?
Lp(a) in der Routinelipiddiagnostik : Methoden und Interferenzen
Untersuchungen zum Lp(a) bei Typ-II-Diabetes
Lp(a) als unabhängiger Risikofaktor für eine KHK
Editorial Lp(a) – the underestimated cardiovascular risk factor
Lp(a) als Risikofaktor einer koronaren Herzkrankheit : eine Grenzwertbestimmung
Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region